ArticleJournal of animal science and biotechnology2026
Glycerol monolaurate attenuates necrotic enteritis in broilers by improving gut-liver health and remodeling the gut microbiota.
Article in Journal of animal science and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNecrotic enteritis (NE) is a widespread avian intestinal disease that causes substantial economic losses in poultry production. With increasing restrictions on antibiotic use, sustainable alternatives are urgently needed. Glycerol monolaurate (GML) has anti-inflammatory and antimicrobial properties, but its role in preventing NE remains unclear. This study aimed to investigate the protective effects of GML on gut-liver health and the cecal microbiota in NE-challenged broilers.
resultsA total of 288 broilers were fed diets supplemented with 1,200 mg/kg GML for 21 d under an NE challenge model. GML improved the average daily gain and jejunal villus height while reducing the intestinal lesion score in NE broilers (P < 0.05). GML upregulated the expression of the tight junction genes OCLN and MUC2 and downregulated the expression of the proinflammatory cytokines interleukin (IL)-1β, IL-8, and tumor necrosis factor (TNF)-α, as well as RELA and IRF5 (P < 0.05). Moreover, GML reduced endotoxin levels and alleviated oxidative stress in the jejunum of NE broilers. NE infection increases intestinal permeability, resulting in elevated serum proinflammatory cytokine (IL-1β, TNF-α) and intestinal-derived endotoxin levels, which subsequently contribute to liver injury. GML significantly alleviated this liver damage, as evidenced by reduced hepatic steatosis and lower serum alanine aminotransferase levels (P < 0.05). Furthermore, GML relieved the NE-induced increase in serum endotoxin and proinflammatory cytokine levels and improved the hepatic antioxidant status by decreasing the malondialdehyde content and increasing superoxide dismutase activity (P < 0.05). Additionally, GML significantly enhanced the alpha diversity indices and increased the relative abundances of Parabacteroides, Lactobacillus, Blautia, and DTU089 in the ceca of NE broilers, with these microbial changes showing significant correlations with improvements in inflammatory and oxidative status. GML altered microbial functions in NE broilers, affecting pathways related to the biosynthesis of unsaturated fatty acids, antibiotic biosynthesis, and phosphonate and phosphinate metabolism. These functional shifts support the potential mechanisms through which the altered microbiota may contribute to the observed improvements.
conclusionsIn summary, GML supplementation alleviated NE in broilers by enhancing intestinal barrier function, reducing inflammation and oxidative stress, and modulating the gut microbiota composition, thereby attenuating gut-derived liver injury and improving growth performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.